The role of deceased donor liver biopsy: An analysis of 5449 liver transplant recipients

• Published in: Clinical transplantation 2020-05, Vol.34 (5), p.e13835-n/a
• Main Authors: Patel, Madhukar S., Mohebali, Jahan, Coe, Taylor M., Sally, Mitchell, Groat, Tahnee, Niemann, Claus U., Malinoski, Darren J., Vagefi, Parsia A.
• Format: Article
• Language: English
• ISSN: 0902-0063; 1399-0012
• DOI: 10.1111/ctr.13835

Background No standard exists for the use of deceased donor liver biopsy during procurement. We sought to evaluate liver biopsy and the impact of findings on outcomes and graft utilization. Methods A prospective observational study of donors after neurologic determination of death was conducted from 02/2012‐08/2017 (16 OPOs). Donor data were collected through the UNOS Donor Management Goals Registry Web Portal and linked to the Scientific Registry of Transplant Recipients (SRTR) for recipient outcomes. Recipients of biopsied donor livers (BxDL) were studied and a Cox proportional hazard analysis was used to identify independent predictors of 1‐year graft survival. Results Data from 5449 liver transplant recipients were analyzed, of which 1791(33%) received a BxDL. There was no difference in graft or patient survival between the non‐BxDL and BxDL recipient groups. On adjusted analysis of BxDL recipients, macrosteatosis (21%‐30%[n = 148] and >30%[n = 92]) was not found to predict 1‐year graft survival, whereas increasing donor age (HR1.02), donor Hispanic ethnicity (HR1.62), donor INR (HR1.18), and recipient life support (HR2.29) were. Conclusions Excellent graft and patient survival can be achieved in recipients of BxDL grafts. Notably, as demonstrated by the lack of effect of macrosteatosis on survival, donor to recipient matching may contribute to these outcomes.